Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
We employ our advanced, specialised process to create targeted libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.
Several key aspects differentiate our library:
partner
Reaxense
upacc
Q15678
UPID:
PTN14_HUMAN
Alternative names:
Protein-tyrosine phosphatase pez
Alternative UPACC:
Q15678; Q5VSI0
Background:
Tyrosine-protein phosphatase non-receptor type 14, also known as Protein-tyrosine phosphatase pez, plays a pivotal role in various cellular processes including lymphangiogenesis, cell adhesion, migration, and growth. It is instrumental in regulating TGF-beta gene expression, influencing epithelial-mesenchymal transition, and modulating beta-catenin dephosphorylation. This protein acts as a negative regulator of YAP, a key component of the hippo pathway, and may function as a tumor suppressor.
Therapeutic significance:
Linked to Choanal atresia and lymphedema, Tyrosine-protein phosphatase non-receptor type 14's involvement in this disease highlights its potential as a target for therapeutic intervention. Understanding its role could open doors to novel treatments for conditions stemming from its dysfunction.